scholarly journals Secondary Primary Lung Cancer After Esophageal Cancer: A Population-Based Study of 44,172 Patients

2020 ◽  
Author(s):  
Yadong Gao ◽  
Jianwei Qiu ◽  
Liugen Gu ◽  
Yanmei Yang ◽  
Haifeng Kang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Esophageal Cancer ◽  
Lung Adenocarcinoma ◽  
Primary Lung Cancer ◽  
Squamous Carcinoma ◽  
Primary Lung Adenocarcinoma ◽  
Significant Difference ◽  
History Of ◽  
Lung Squamous Carcinoma

Abstract Background: The present study aimed to assess the incidence, characteristics, and survival of secondary primary lung cancer after primary esophageal cancer (EC-LC). Methods: The patients with esophageal cancer (EC) who developed SPLC and patients with first primary lung cancer (LC-1) were retrospectively reviewed in the Surveillance, Epidemiology, and End Results 18 registries covering 2000 to 2016. The risk of secondary primary lung cancer using standardized incidence ratio (SIR) was calculated among patients with EC. Overall survival and characteristics were compared between patients with EC-LC and patients with LC-1.Results: In comparison with the general population, the patients with EC had a higher risk for developing secondary primary lung cancer (SIR =1.86, 95% confidence interval (CI): 1.69-2.05). There was a significant difference with regard to the year of diagnosis, sex, grade and stage between the secondary primary lung squamous carcinoma after EC (EC-LUSC) and first primary lung squamous carcinoma (LUSC-1) patients. A statistically significant difference with respect to race, sex, age, year, grade and stage was found between the secondary primary lung adenocarcinoma after EC (EC-LUAD) and first primary lung adenocarcinoma (LUAD-1) patients. A history of EC was found to be an independent risk factor of death for lung squamous carcinoma and lung adenocarcinoma patients in localized stage based on multivariate Cox regression analysis, propensity score-matching analysis and multiple imputation.Conclusion: There is a significantly increased risk of secondary primary lung cancer in EC survivors and a history of EC adversely affects overall survival in individuals who subsequently develop localized EC-LUSC and EC-LUAD. Clinicians should moderately strengthen lung tissue protection during the management of EC patients.

Incidence of venous thromboembolism in lung cancer and its effect on survival.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7102-7102
Author(s):  
Mohammad Mozayen ◽  
Anteneh A. Tesfaye ◽  
Manas ranjan Sarangi ◽  
Jyothsna Talluri ◽  
Khalil Katato
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Venous Thromboembolism ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Squamous Carcinoma ◽  
Small Cell ◽  
Secondary Outcome ◽  
Small Cell Lung ◽  
Significant Difference

7102 Background: Lung cancer is a major risk factor of venous thromboembolism (VTE). The incidence of VTE in different histological patterns of lungs cancer and its impact at the disease outcome is not well studied. We aim to evaluate the incidence rate of VTE in lung cancer and its effect on survival. Methods: Patients (pts) with lung cancer diagnosis from cancer database of community hospital were reviewed. Pts’ medical records were checked for VTE over 3 years after diagnosis. Pts’ demographics, pathology, TNM stage and overall survival were studied. Development of VTE was primary outcome and 3 year overall survival was the secondary outcome. Results: A total 2,164 pts with lung cancer between 1995 and 2008 were included. Median age of the study population was 70 years. Males were 53%, African Americans were 7%. 200 pts (9%) were diagnosed with VTE. Out of 1783 pts with non-small cell lung cancer (NSCLC), 176 pts (9.9%) had VTE whereas out of 381 pts with small cell lung cancer (SCLC) 24 pts (6.3%) had VTE (p=0.015). Among NSCLC pts, 13.5% of pts with adenocarcinoma had VTE, whereas 6.6% of pts with squamous cell carcinoma had VTE (p<0.05). The incidence of VTE in stages I, II, III, IV of all pts were (8.4%, 7.3%, 13%, 7.5%) (p=0.007) respectively. In NSCLC, three years overall survival of pts with and without VTE was 22% and 24% respectively (p=0.34). In SCLC, three years overall survival of pts with and without VTE was 21% and 11% respectively (p=0.09). Conclusions: There is a higher incidence of VTE in non-small cell lung cancer than in small cell lung cancer. Among the NSCLC, VTE’s incidence was higher in adenocarcinoma than squamous carcinoma. VTE maybe higher at advanced stages (stage III) in both NSCLC and SCLC combined. There was no significant difference in the 3 years overall survival of lung cancer patients with and without VTE.

scholarly journals Detection of EGFR Mutation of Pulmonary Adenocarcinoma in Sputum using Droplet Digital PCR

2021 ◽  
Author(s):  
Tetsuya Isaka ◽  
Tomoyuki Yokose ◽  
Hiroyuki Ito ◽  
Haruhiko Nakayama ◽  
Yohei Miyagi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Tumor Size ◽  
Mutation Detection ◽  
Egfr Mutation ◽  
Lung Tumor ◽  
Primary Lung Cancer ◽  
Resected Specimen ◽  
Sputum Cytology ◽  
Primary Lung Adenocarcinoma

Abstract Background】It is still unclear whether epidermal growth factor receptor (EGFR) mutation of primary lung adenocarcinoma can be detected accurately on sputum samples. This study aimed to examine EGFR mutations of primary lung adenocarcinoma in sputum samples using droplet digital polymerase chain reaction (ddPCR) and compare it with an EGFR mutation in surgically resected lung cancer. 【Methods】Sputum was collected preoperatively from patients with primary lung cancer who were scheduled for complete resection of lung tumor at Kanagawa Cancer Center from September 2014 to May 2016. ddPCR was performed to detect EGFR exon 21 L858R point mutation (Ex21 mutation) and EGFR exon 19 deletion mutation (Ex19 mutation) in the sputum samples. The concordance of EGFR mutation status in sputum samples and tumors in surgically resected specimen was evaluated for each positive and negative cytology group.【Results】One hundred and eighteen patients with primary lung adenocarcinoma provided sputum samples. Sputum cytology was positive in 13 patients (11.0%). ddPCR detected two cases of Ex21 mutation and two cases of Ex19 mutation. Compared to surgically resected specimens, the sensitivity, specificity, and positive predictive value of EGFR mutation detection were 80.0%, 100%, and 92.3%, respectively. The sensitivity of EGFR mutation detection was 3.1% in sputum cytology negative cases. Logistic regression model analysis revealed that tumor size ≥ 29 mm determined using computed tomography (CT) was an independent potential predictive factor for positive sputum cytology (odds ratio = 10.6, 95% confidence interval: 1.85–61.0, p=0.008).【Conclusions】EGFR mutation of primary lung adenocarcinoma was accurately detected in sputum samples using ddPCR if the sputum cytology was positive. Sputum samples should be collected in patients with CT tumor size ≥ 29 mm for EGFR mutation analysis.

scholarly journals Previous Extrapulmonary Malignancies Impact Outcomes in Patients With Surgically Resected Lung Cancer

2021 ◽  
Vol 8 ◽  
Author(s):  
Hsin-Ying Lee ◽  
Min-Shu Hsieh ◽  
Hsien-Chi Liao ◽  
Pei-Hsing Chen ◽  
Xu-Heng Chiang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Thyroid Cancer ◽  
Medical Records ◽  
Primary Lung Cancer ◽  
Clinicopathological Parameters ◽  
Second Primary ◽  
Patients With Cancer ◽  
History Of ◽  
Second Primary Malignancies

Background: As the overall survival of patients with cancer continues to improve, the incidence of second primary malignancies seems to be increasing. Previous studies have shown controversial results regarding the survival of patients with primary lung cancer with previous extrapulmonary malignancies. This study aimed to determine the clinical picture and outcomes of this particular subgroup of patients.Materials and Methods: We included 2,408 patients who underwent pulmonary resection for primary lung cancer at our institute between January 1, 2011 and December 30, 2017 in this retrospective study. Medical records were extracted and clinicopathological parameters and postoperative prognoses were compared between patients with lung cancer with and without previous extrapulmonary malignancies.Results: There were 200 (8.3%) patients with previous extrapulmonary malignancies. Breast cancer (30.5%), gastrointestinal cancer (17%), and thyroid cancer (9%) were the most common previous extrapulmonary malignancies. Age, sex, a family history of lung cancer, and preoperative carcinoembryonic antigen levels were significantly different between the two groups. Patients with previous breast or thyroid cancer had significantly better overall survival than those without previous malignancies. Conversely, patients with other previous extrapulmonary malignancies had significantly poorer overall survival (p &lt; 0.001). The interval between the two cancer diagnoses did not significantly correlate with clinical outcome.Conclusion: Although overall survival was lower in patients with previous extrapulmonary malignancies, previous breast or thyroid cancer did not increase mortality. Our findings may help surgeons to predict prognosis in this subgroup of patients with primary lung cancer.

scholarly journals Radiotherapy for brain metastasis and long-term survival

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kawngwoo Park ◽  
Gi Hwan Bae ◽  
Woo Kyung Kim ◽  
Chan-Jong Yoo ◽  
Cheol Wan Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Primary Lung Cancer ◽  
Whole Brain Radiotherapy ◽  
Term Survival ◽  
Brain Radiotherapy ◽  
Survival Difference ◽  
Significant Difference

AbstractPatients with brain metastases (BM) can benefit from radiotherapy (RT), although the long-term benefits of RT remain unclear. We searched a Korean national health insurance claims database and identified 135,740 patients with newly diagnosed BM during 2002–2017. Propensity score matching (PSM) was used to evaluate survival according to RT modality, which included whole-brain radiotherapy (WBRT) and/or stereotactic radiosurgery (SRS). The 84,986 eligible patients were followed for a median interval of 6.6 months, and 37,046 patients underwent RT (43.6%). After the PSM, patients who underwent RT had significantly better overall survival after 1 year (42.4% vs. 35.3%, P < 0.001), although there was no significant difference at 2.6 years, and patients who did not undergo RT had better survival after 5 years. Among patients with BM from lung cancer, RT was also associated with a survival difference after 1 year (57.3% vs. 32.8%, P < 0.001) and a median survival increase of 3.7 months. The 1-year overall survival rate was significantly better for SRS than for WBRT (46.4% vs. 38.8%, P < 0.001). Among Korean patients with BM, especially patients with primary lung cancer, RT improved the short-term survival rate, and SRS appears to be more useful than WBRT in this setting.

Diagnosis and management of a metastatic mixed gestational trophoblastic neoplasia with synchronous primary lung cancer

2021 ◽  
Vol 14 (5) ◽  
pp. e240606
Author(s):  
Varun Iyengar ◽  
Hetal Mistry ◽  
Catherine Hibbitt ◽  
Alexei Shimanovsky
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Combination Chemotherapy ◽  
Primary Lung Cancer ◽  
Pulmonary Nodules ◽  
Holistic Care ◽  
Gestational Trophoblastic Neoplasia ◽  
Primary Lung Adenocarcinoma ◽  
Rare Tumours

Mixed gestational trophoblastic neoplasias (GTNs) are rare placental tumours that arise from abnormal fertilisation events. To date, only 34 patients with mixed GTNs have been reported in the literature. As such, the management of such cases remains challenging. This report presents a case of a mixed GTN that was further complicated by a synchronous primary lung adenocarcinoma. Our patient was initially treated with hysterectomy, with surveillance labwork showing persistence of her malignancy. She then began combination chemotherapy, at the end of which she appeared to be in remission clinically. Unfortunately, subsequent imaging showed the persistence of pulmonary nodules that were ultimately resected, demonstrating a new primary lung adenocarcinoma. At present, she remains free of both cancers 2 years after her initial diagnosis. The complexity of this case underscores the importance of patient-centred treatment for rare tumours and the role of a multidisciplinary team in the effort to provide holistic care.

scholarly journals Detection of EGFR Mutation of Pulmonary Adenocarcinoma in Sputum Using Droplet Digital PCR

2020 ◽  
Author(s):  
Tetsuya Isaka ◽  
Tomoyuki Yokose ◽  
Hiroyuki Ito ◽  
Haruhiko Nakayama ◽  
Yohei Miyagi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Tumor Size ◽  
Mutation Detection ◽  
Egfr Mutation ◽  
Lung Tumor ◽  
Primary Lung Cancer ◽  
Resected Specimen ◽  
Sputum Cytology ◽  
Primary Lung Adenocarcinoma

Abstract Background It is still unclear whether epidermal growth factor receptor (EGFR) mutation of primary lung adenocarcinoma can be detected accurately on sputum samples. This study aimed to examine EGFR mutations of primary lung adenocarcinoma in sputum samples using droplet digital polymerase chain reaction (ddPCR) and compare it with an EGFR mutation in surgically resected lung cancer. Methods Sputum was collected preoperatively from patients with primary lung cancer who were scheduled for complete resection of lung tumor at Kanagawa Cancer Center from September 2014 to May 2016. ddPCR was performed to detect EGFR exon 21 L858R point mutation (Ex21 mutation) and EGFR exon 19 deletion mutation (Ex19 mutation) in the sputum samples. The concordance of EGFR mutation status in sputum samples and tumors in surgically resected specimen was evaluated for each positive and negative cytology group.Results One hundred and eighteen patients with primary lung adenocarcinoma provided sputum samples. Sputum cytology was positive in 13 patients (11.0%). ddPCR detected two cases of Ex21 mutation and two cases of Ex19 mutation. Compared to surgically resected specimens, the sensitivity, specificity, and positive predictive value of EGFR mutation detection were 80.0%, 100%, and 92.3%, respectively. The sensitivity of EGFR mutation detection was 3.1% in sputum cytology negative cases. Logistic regression model analysis revealed that tumor size ≥ 29 mm determined using computed tomography (CT) was an independent potential predictive factor for positive sputum cytology (odds ratio = 10.6, 95% confidence interval: 1.85–61.0, p=0.008).Conclusions EGFR mutation of primary lung adenocarcinoma was accurately detected in sputum samples using ddPCR if the sputum cytology was positive. Sputum samples should be collected in patients with CT tumor size ≥ 29 mm for EGFR mutation analysis.

scholarly journals Identification of Potential Long Non-coding RNA Expression Quantitative Trait Methylations in Lung Adenocarcinoma and Lung Squamous Carcinoma

2020 ◽  
Vol 11 ◽  
Author(s):  
Xiaohong Wu ◽  
Yue Gao ◽  
Jianlong Bu ◽  
Lin Deng ◽  
Pinyi Zhang ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Quantitative Trait ◽  
Regulatory Networks ◽  
Squamous Carcinoma ◽  
Drug Repurposing ◽  
Cancer Pathogenesis ◽  
Non Coding Rna ◽  
Wide Range ◽  
Lung Squamous Carcinoma ◽  
Long Non Coding Rna

There are associations between DNA methylation and the expression of long non-coding RNA (lncRNA), also known as lncRNA expression quantitative trait methylations (lnc-eQTMs). Lnc-eQTMs may induce a wide range of carcinogenesis pathways. However, lnc-eQTMs have not been globally identified and studied, and their roles in lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) are largely unknown. In the present study, we identified some differential methylation sites located in genes of long intergenic non-coding RNAs (lincRNAs) and other types of lncRNAs in LUAD and LUSC. An integrated pipeline was established to construct two global cancer-specific regulatory networks of lnc-eQTMs in LUAD and LUSC. The associations between eQTMs showed common and specific features between LUAD and LUSC. Some lnc-eQTMs were also related with survival in LUAD- and LUSC-specific regulatory networks. Lnc-eQTMs were associated with cancer-related functions, such as lung epithelium development and vasculogenesis by functional analysis. Drug repurposing analysis revealed that these lnc-eQTMs may mediate the effects of some anesthesia-related drugs in LUAD and LUSC. In summary, the present study elucidates the roles of lnc-eQTMs in LUAD and LUSC, which could improve our understanding of lung cancer pathogenesis and facilitate treatment.

scholarly journals EPID-07. HEMATOLOGICAL ADVERSE EVENTS IN GLIOBLASTOMA PATIENTS TREATED WITH TEMOZOLOMIDE

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi75-vi76
Author(s):  
Catherine Garcia ◽  
Zin Myint ◽  
Rani Jayswal ◽  
Allison Butts ◽  
Heidi Weiss ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adverse Events ◽  
Protective Factor ◽  
Significant Proportion ◽  
Progression Free Survival ◽  
Free Survival ◽  
Significant Difference ◽  
History Of ◽  
Grade 3 ◽  
Severe Grade

Abstract BACKGROUND Temozolomide (TMZ) is the cornerstone for glioblastoma (GBM) treatment. A significant proportion of patients develops hematologic toxicities with limited investigations on outcomes and risk factors for their development. METHODS Our study combines data from the two largest group trials, RTOG 0525 and RTOG 0825, to analyze serious hematologic adverse events (HAE) associated with TMZ therapy for GBM. We analyzed frequency and outcomes of HAE during chemoradiation. RESULTS 1154 patients were evaluated with a median age of 57 years. Over 79% of patients developed HAE during the entire course of GBM treatment. During chemoradiation the most common HAE during chemoradiation was lymphopenia (41.5%), followed by thrombocytopenia (39.0%), and anemia (35.3%). Of these, 34.1% were severe (Grade 3 or 4) and 65.9% were mild (grade 1 or 2). During maintenance the most common HAE was leukopenia (50.7%), followed by neutropenia (50.4%), and lymphopenia (45.3%). MGMT methylation was not associated with HAEs. A history of HAEs during chemoradiation was a protective factor for developing HAEs during maintenance. MGMT methylated and age younger than 50 were protective factors for mortality. Patients that presented HAEs anytime during treatment had a longer overall survival and progression free survival. There was no significant difference in survival between mild or severe HAEs. CONCLUSION HAE are common during chemoradiation with TMZ for GBM, but are more commonly grade 1 or 2 per CTCAE. HAE during GBM treatment is associated with decreased progression free survival and overall survival.

scholarly journals An elderly female patient with ROS1 rearrangement primary lung adenocarcinoma and breast carcinoma: a rare case report and review of the literature

2019 ◽  
Vol 2 (3) ◽  
pp. 197-203 ◽  
Author(s):  
Xiaojuan Yang ◽  
Diyuan Qin ◽  
Yu Zhang ◽  
Xue Li ◽  
Ning Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Elderly Patients ◽  
Lung Adenocarcinoma ◽  
Female Patient ◽  
Malignant Tumors ◽  
Primary Lung Cancer ◽  
Lung Cancer Mortality ◽  
Anaplastic Lymphoma ◽  
Reduced Dose

Abstract We report the case of a 90-year-old female patient who was suffering from c-ros oncogene 1 (ros-1) rearrangement adenocarcinoma and breast cancer. After about 14 months of a reduced dose of crizotinib treatment, she had a stable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). This patient’s case demonstrates that ros-1 rearrangements are not limited to patients of young age. In addition, this case indicates that crizotinib, as second-line, or even first-line, treatment may be effective and manageable in elderly patients. Furthermore, for elderly patients carrying a ros1 fusion, a reduced dose of crizotinib may be efficacious rather than a resistance factor. Based on our findings, we recommend that elderly patients with advanced lung adenocarcinoma should be considered for inclusion in molecular screening for ros-1 translocation, especially for never-smokers negative for epidermal growth factor receptor (egfr) mutation and the fusion between echinoderm microtubule associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK). This deserves attention because the population is aging, with increasing incidence and morbidity of multiple primary malignant tumors. Neglect of breast nodules at the onset is one of the limitations of our case, as combination of primary lung cancer with breast cancer is common. Above all, use of antiestrogens before and after the diagnosis of non-small-cell lung cancer is related to a reduced risk of lung cancer mortality. Therefore, careful attention should always be paid to these cases.

Sign in / Sign up

Export Citation Format

Share Document